A Phase 1 interventional study of BIO 300 Oral Suspension in Healthy Volunteer Study, sponsored by Humanetics Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Humanetics Corporation · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a two-part study of BIO 300 Oral Suspension in healthy male and female volunteers. The first part is a multiple ascending dose (MAD) study to test the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the drug when given as daily doses over 14 days. The study will enroll three cohorts each receiving a different daily dose: 2000 mg, 3000 mg, or 4000 mg. A fourth group may be added depending on results on the first three cohorts. Each cohort will include 10 participants (5 men, 5 women), with at least 8 completing all study steps. Participants will follow a special diet low in soy-based foods and will fast before certain doses. Blood samples and health checks will be done throughout the study to assess safety, drug is absorption and distribution in the body (PK), and its effects (PD). Safety will be reviewed after each group finishes to decide if the next dose level is safe to proceed.
The second part of the study is a food effect study to examine how food effects the PK of a single dose of BIO 300 Oral Suspension. This study will enroll 16 participants (8 men, 8 women) and will be split into two groups: one group will take the drug after fasting for 10 hours and the other will take the drug after eating a high-fat meal. After a 7-day break, participants will switch conditions (the previously fasted group will take the drug with food, and the previously fed group will take the drug after fasting). Blood samples and health checks will measure how food influences drug absorption (PK) and safety. Both the MAD study and food effect study aim to ensure the drug is safe and provide data on how it behaves in the body under different conditions.
Part 1: Multiple Ascending Dose Study (MAD): Open-label, ascending dose given once daily for 14 days in healthy volunteers. The study will enroll 3 cohorts (dose levels) sequentially, each with 10 participants (5F/5M) per cohort, so that a minimum of 8 study participants (4F/4M) per cohort complete all study procedures. Participants will follow a diet low in soy isoflavones for 7 days before, during and 7 days after treatment and will be required to fast at least 10 hours before the first, sixth and last dose. BIO 300 Oral Suspension will be administered starting on day 1. The first cohort, Cohort 1, will be administered BIO 300 Oral Suspension at 2000 mg/day once daily for 14 days. If dose escalation criteria are met, Cohort 2 will be administered 3000 mg/day, and similarly if dose escalation criteria are met following Cohort 2, then Cohort 3 will be administered 4000 mg/day. Following the completion of Cohort 3, there will be an option to enroll a fourth cohort at a higher or lower dose depending on the outcomes of the first three cohorts. Participants will be administered BIO 300 Oral Suspension daily during their scheduled clinic visits. Participants will remain in the clinic 12 hours after the first dose, sixth dose and last dose and for observations and blood sample collection for clinical lab assessment, pharmacokinetics (PK) and pharmacodynamics (PD). On the day 1, 6 and 14, participants will remain fasted after dosing for 4 hours until provided a standardized low soy meal after the 4 hour blood draw and after the 8 hour blood draw. Blood sampling and/or observations will be performed on dosing days 1-14 as described in the schedule of events. Participants will return to the clinic on days 15, 16 and 21 after their final dose for blood sampling and/or observations as detailed in the schedule of events. Safety data will be reviewed after the completion of each cohort to approve dose escalation. At the conclusion of all three cohorts, all data will be analyzed to assess safety, PK and PD. If the optional fourth cohort is enrolled, all data (safety, PK and PD) from the fourth cohort will be analyzed at the conclusion of the cohort.
Part 2: Food Effect Study: Following the MAD study, an open-label, single-dose food effect study in healthy volunteers will be conducted. The study will enroll 16 participants (8F/8M), so that a minimum of 12 study participants (6F/6M) complete all study procedures. Study participants will be randomized 1:1 into two cohorts. Cohort 1 will be administered a single BIO 300 Oral Suspension dose under fasted conditions and Cohort 2 will be administered a single BIO 300 Oral Suspension dose under fed conditions. After a 7 day washout period, participants in cohort 1 will receive another dose of BIO 300 Oral Suspension under fed conditions and participants in cohort 2 will receive another dose of BIO 300 Oral Suspension under fasted conditions (cross over design). All participants will follow a diet low in soy isoflavones for 7 days before dosing, during the washout period and for 7 days after dosing. The planned BIO 300 Oral Suspension dose used in this study will be 3000 mg, however this is subject to change following safety and PK data review following the completion of the MAD study above. For fasted dosing, participants will be required to fast for at least 10 hours prior to dosing and for 4 hours after dosing. For fed dosing, participants will receive an FDA-approved high-fat meal with no substitutions (800-1000 calories; approximately 50% of calories derived from fat) following an overnight fast of at least 10 hours. The entire meal will be consumed within 30 minutes, dosing will begin 30 minutes after starting the meal, and participants will fast for 4 hours after dosing. All participants will remain in the clinic 12 hours after each dose for observations and blood sample collection for clinical lab assessment, and PK. All participants will remain fasted (fasted cohort) or fast (fed cohort) after dosing for 4 hours until provided a standardized low soy meal after the 4 hour blood draw and after the 8 hour blood draw. Participants will return to the clinic on day 2 and 3 after dosing for blood sampling and/or observations as detailed in the schedule of events (day 10 and 11 after the second dose). At the conclusion of the study, data will be analyzed from both cohorts to determine safety and PK.
Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
INCLUSION: In order to be eligible to participate in this study, an individual must meet all of the following criteria:
At the discretion of the Investigator, blood routine, liver and kidney functions are within the controllable range.
EXCLUSION: An individual who meets any of the following criteria will be excluded from participation in this study:
Study participants with any of the following are not eligible;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The multiple ascending dose study has a single arm. Three cohorts are enrolled sequentially and given ascending doses of study intervention.
Drug: BIO 300 Oral Suspension
Food effect study arm that is administered the study intervention first under fed conditions and then under fasted conditions following crossover.
Drug: BIO 300 Oral Suspension
Food effect study arm that is administered the study intervention first under fasted conditions and then under fed conditions following crossover.
Drug: BIO 300 Oral Suspension
Suspension of genistein nanoparticles for oral administration
Also known as: genistein nanosuspension
Describe the overall adverse event profile of BIO 300 Oral Suspension in healthy volunteers following repeat dosing or single doses under fed and fasted conditions
Report the incidence and severity of BIO 300 Oral Suspension-related adverse events following 14 days of once daily administration and single doses administered under fed vs fasted conditions as assessed by CTCAE v5.0
Time frame: Up to 7 days after the last dose
Describe the effects of multiple ascending doses of BIO 300 Oral Suspension on gene expression in the blood as assessed by RNA sequencing
Assess changes in differential gene expression in the whole blood related to BIO 300 Oral Suspension after 1, 6 and 14 days of dosing.
Time frame: From enrollment to the end of treatment at 14 days
Describe the effects of multiple ascending doses of BIO 300 Oral Suspension on protein expression in the blood as assessed by proximity extension assay
Assess changes in protein expression in the blood serum related to BIO 300 Oral Suspension after 1, 6 and 14 days of dosing.
Time frame: From enrollment to the end of treatment at 14 days
Identify serum metabolites of genistein after single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report the serum metabolites of genistein and their relative abundance after 1 or 14 days of dosing
Time frame: From enrollment to 48 hours after the last dose
Evaluate the potential for BIO 300 Oral Suspension to prolongate the corrected QT (QTc) interval following single and repeat doses
Change in QTc interval relative to baseline following a single dose of BIO 300 Oral Suspension administered under fasted conditions
Time frame: From enrollment to 24 hours dosing
Evaluate the potential for BIO 300 Oral Suspension to prolongate the corrected QT (QTc) interval following single and repeat doses
Change in QTc interval relative to baseline following a single dose and 14 repeat doses of BIO 300 Oral Suspension
Time frame: From enrollment to 24 hours after the first dose and the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report area under the serum concentration versus time curve (AUC) after 1 dose
Time frame: 48 hours after the dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report area under the serum concentration versus time curve (AUC) after 6 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report area under the serum concentration versus time curve (AUC) after 14 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report peak serum concentration (Cmax) after 1 dose
Time frame: 48 hours after the dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report peak serum concentration (Cmax) after 6 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report peak serum concentration (Cmax) after 14 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report time to peak serum concentration (Tmax) after 1 dose
Time frame: 48 hours after the dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report time to peak serum concentration (Tmax) after 6 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report time to peak serum concentration (Tmax) after 14 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report half-life (T1/2) after 1 dose
Time frame: 48 hours after the dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report half-life (T1/2) after 6 once daily doses
Time frame: 48 hours after the last dose
Establish the PK of single and repeat doses of BIO 300 Oral Suspension under fed or fasted conditions
Report half-life (T1/2) after 14 once daily doses
Time frame: 48 hours after the last dose
Plan to share: Yes — Only IPD used in the results publication
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning at the time of results publication with no end date
Ran from Dec 2024 to primary completion in Aug 2025, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Genistein-based BIO 300
Acute Radiation Syndrome
Humanetics Corporation